1. Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance
- Author
-
Ekaterina A. Nabatchikova, Sergey Moiseev, D.T. Abdurakhmanov, E N Nikulkina, T. P. Rozina, and Vladimir Chulanov
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Sofosbuvir ,Salvage therapy ,Hepacivirus ,Drug resistance ,Antiviral Agents ,chemistry.chemical_compound ,Pegylated interferon ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Treatment Failure ,Salvage Therapy ,Pharmacology ,business.industry ,Ribavirin ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Clinical trial ,Multiple drug resistance ,Treatment Outcome ,Infectious Diseases ,chemistry ,Retreatment ,Drug Therapy, Combination ,Female ,business ,Biomarkers ,medicine.drug - Abstract
Despite very high efficacies of direct-acting antivirals (DAAs) reported in clinical trials, treatment failure in real-life practice can occur in 5–10% of cases and is mostly associated with emergence of resistance-associated substitutions (RASs). Little is known about the efficacy of retreatment in these patients, especially in those with decompensated cirrhosis, and only a few retreatment studies have been performed so far. Here we present case reports of successful sofosbuvir-based treatment in patients with advanced class B cirrhosis with prior pegylated interferon/ribavirin and all-oral DAA failure with multiclass drug resistance. HCV resistance testing at failure was performed to guide the choice of salvage therapy.
- Published
- 2017
- Full Text
- View/download PDF